Anti-nerve growth factor antibody attenuates chronic morphine treatment-induced tolerance in the rat.
Nerve growth factor (NGF) is known to induce inflammation and pain; however its role in opioid-induced tolerance has not been studied. This study investigated the effects of an anti-NGF neutralizing antibody on the development of tolerance following chronic morphine treatment in naïve rats.



Four groups of rats were used in this study; one treated with saline alone, one with 10 mg/kg of morphine, one with 10 μg of anti-NGF and the other with 10 mg/kg of morphine + 10 μg of anti-NGF, twice per day for 5 days. The route of treatment was subcutaneous (S.C.) for morphine and saline, and intraperitoneal (i.p.) for anti-NGF. Response to a noxious thermal stimulus during the course of drug treatment was assessed (Hargreaves' test). Further, the change in the NGF levels in the lumbar spinal cord was measured by ELISA.



Our results showed that repeated administration of morphine produced an apparent tolerance which was significantly attenuated by co-administration of anti-NGF (P < 0.001). Additionally, the area under the curve (AUC) of the analgesic effect produced by the combination of morphine and anti-NGF was significantly (P < 0.001) greater than for saline controls and chronic morphine treated rats. Moreover, the level of NGF in the spinal cord of chronic morphine treated rats was significantly higher (P < 0.05) than in both the saline control group and the group receiving simultaneous administration of anti-NGF with morphine. These results indicate that anti-NGF has the potential to attenuate morphine-induced tolerance behavior by attenuating the effects of NGF at the spinal level.



Taken together, our study strongly suggests that the NGF signaling system is a potential novel target for treating opioid-induced tolerance.
Burn Injuries Task Area, United States Army Institute of Surgical Research, 3698 Chambers Pass, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas, 78234, USA. bopaiah.p.cheppudira.vol@mail.mil.
Bopaiah P
BP
Cheppudira
Burn Injuries Task Area, United States Army Institute of Surgical Research, 3698 Chambers Pass, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas, 78234, USA.
Alex V
AV
Trevino
Department of Clinical Investigation, United States Army Institute of Surgical Research, 3698 Chambers Pass, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas, 78234, USA.
Lawrence N
LN
Petz
Burn Injuries Task Area, United States Army Institute of Surgical Research, 3698 Chambers Pass, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas, 78234, USA.
Robert J
RJ
Christy
Burn Injuries Task Area, United States Army Institute of Surgical Research, 3698 Chambers Pass, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas, 78234, USA.
John L
JL
Clifford
D000279:Administration, Cutaneous; D000818:Animals; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000494:pharmacology*; D004361:Drug Tolerance / Q000276:immunology*; D007274:Injections, Intraperitoneal; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D020932:Nerve Growth Factor / Q000276:immunology* / Q000378:metabolism; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D013116:Spinal Cord / Q000378:metabolism
D057134:Antibodies, Neutralizing; D009020:Morphine; D020932:Nerve Growth Factor
Anti-NGF; Hargreaves’ test; Morphine; Nerve growth factor; Tolerance